204 related articles for article (PubMed ID: 30864265)
1. Dismantling the bacterial virulence program.
Alford MA; Pletzer D; Hancock REW
Microb Biotechnol; 2019 May; 12(3):409-413. PubMed ID: 30864265
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition.
Fleitas Martínez O; Cardoso MH; Ribeiro SM; Franco OL
Front Cell Infect Microbiol; 2019; 9():74. PubMed ID: 31001485
[TBL] [Abstract][Full Text] [Related]
3. Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability.
Totsika M
Future Med Chem; 2017 Mar; 9(3):267-269. PubMed ID: 28207349
[No Abstract] [Full Text] [Related]
4. Disarming bacterial virulence through chemical inhibition of the DNA binding domain of an AraC-like transcriptional activator protein.
Yang J; Hocking DM; Cheng C; Dogovski C; Perugini MA; Holien JK; Parker MW; Hartland EL; Tauschek M; Robins-Browne RM
J Biol Chem; 2013 Oct; 288(43):31115-26. PubMed ID: 24019519
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobials: targeting virulence genes necessary for intracellular multiplication.
Liautard JP; Jubier-Maurin V; Boigegrain RA; Köhler S
Trends Microbiol; 2006 Mar; 14(3):109-13. PubMed ID: 16469497
[TBL] [Abstract][Full Text] [Related]
6. Novel agents to inhibit microbial virulence and pathogenicity.
Escaich S
Expert Opin Ther Pat; 2010 Oct; 20(10):1401-18. PubMed ID: 20718591
[TBL] [Abstract][Full Text] [Related]
7. Sortase A: an ideal target for anti-virulence drug development.
Cascioferro S; Totsika M; Schillaci D
Microb Pathog; 2014 Dec; 77():105-12. PubMed ID: 25457798
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic heterogeneity: a bacterial virulence strategy.
Weigel WA; Dersch P
Microbes Infect; 2018; 20(9-10):570-577. PubMed ID: 29409898
[TBL] [Abstract][Full Text] [Related]
9. H-NOX proteins in the virulence of pathogenic bacteria.
Lee-Lopez C; Yukl E
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34939646
[TBL] [Abstract][Full Text] [Related]
10. Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.
Russo TA; Spellberg B; Johnson JR
J Infect Dis; 2016 Mar; 213(6):901-3. PubMed ID: 26563238
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies for the application of aminoglycoside antibiotics against the biofilm-forming human pathogenic bacteria.
Khan F; Pham DTN; Kim YM
Appl Microbiol Biotechnol; 2020 Mar; 104(5):1955-1976. PubMed ID: 31970432
[TBL] [Abstract][Full Text] [Related]
12. Natural Products That Target Virulence Factors in Antibiotic-Resistant
Wu SC; Liu F; Zhu K; Shen JZ
J Agric Food Chem; 2019 Dec; 67(48):13195-13211. PubMed ID: 31702908
[TBL] [Abstract][Full Text] [Related]
13. Specific Antivirulence Activity, A New Concept for Reliable Screening of Virulence Inhibitors.
Defoirdt T
Trends Biotechnol; 2016 Jul; 34(7):527-529. PubMed ID: 26879186
[TBL] [Abstract][Full Text] [Related]
14. Interference With Quorum-Sensing Signal Biosynthesis as a Promising Therapeutic Strategy Against Multidrug-Resistant Pathogens.
Fleitas Martínez O; Rigueiras PO; Pires ÁDS; Porto WF; Silva ON; de la Fuente-Nunez C; Franco OL
Front Cell Infect Microbiol; 2018; 8():444. PubMed ID: 30805311
[TBL] [Abstract][Full Text] [Related]
15. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies.
de la Fuente-Núñez C; Reffuveille F; Fernández L; Hancock RE
Curr Opin Microbiol; 2013 Oct; 16(5):580-9. PubMed ID: 23880136
[TBL] [Abstract][Full Text] [Related]
16. [Target-specific screening of antivirulence preparations for chronic infection therapy].
Zigangirova NA; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2011; (4):107-15. PubMed ID: 21913401
[TBL] [Abstract][Full Text] [Related]
17. Deletion of the vacJ gene affects the biology and virulence in Haemophilus parasuis serovar 5.
Zhao L; Gao X; Liu C; Lv X; Jiang N; Zheng S
Gene; 2017 Mar; 603():42-53. PubMed ID: 27988234
[TBL] [Abstract][Full Text] [Related]
18. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.
Ogawara H
J Antibiot (Tokyo); 2021 Jan; 74(1):24-41. PubMed ID: 32647212
[TBL] [Abstract][Full Text] [Related]
19. Relationship between antibiotic resistance, biofilm formation, genes coding virulence factors and source of origin of
Ratajczak M; Kamińska D; Nowak-Malczewska DM; Schneider A; Dlugaszewska J
Ann Agric Environ Med; 2021 Jun; 28(2):306-313. PubMed ID: 34184515
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Adaptations of Intracellullar Bacterial Pathogens and their Mammalian Host Cells during Infection ("Pathometabolism").
Eisenreich W; Heesemann J; Rudel T; Goebel W
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
